natgillin/translations-raw huggingface dataset:
Celoten proračun bo znašal dve milijardi evrov za obdobje od 2007 do 2013.
The total budget will be € 2 billion for the period 2007-2013.
Prispevek Skupnosti bo znašal milijardo evrov.
The contribution from the Community will be € 1 billion.
Enak znesek bodo prispevala farmacevtska podjetja, dejavna na področju raziskav, in sicer v obliki osebja, laboratorijske opreme, kliničnih raziskav itd.
This public funding will be matched by equal contributions from research based pharmaceutical companies, in form of staff, laboratory equipment, clinical research etc.
Prispevek Skupnosti bo namenjen izključno malim in srednje velikim podjetjem, neprofitnim organizacijam, visokošolskim ustanovam, oblastem, kliničnim centrom ali organizacijam pacientov, in ne velikim podjetjem.
Community funding will go exclusively to SMEs, non-profit organisations, academia, authorities, clinical centres or patient organisations - not to big companies.
Pripravljavka mnenja toplo pozdravlja ustanovitev skupnega podjetja za pobudo za inovativna zdravila, ki bo pospešilo razvoj inovativnih zdravil, ki bodo hitreje prišla do bolnikov in bodo bolj ustrezala njihovim potrebam.
The draftsman warmly welcomes IMI Joint Undertaking which will speed up the development of innovative medicines that reach patients faster and are better fitted to their needs.
Pobuda bo prinesla tudi zmanjšanje tveganja pri kliničnih preskusih na ljudeh.
The Initiative will also result in less risk through human clinical trials.
Znanstveni in tehnološki napredek v kombinaciji z boljšim poznavanjem človeškega genoma omogočata razvoj popolnoma novega pristopa k boju proti boleznim.
The scientific and technological progress combined with better knowledge of the human genome allows the development of entirely new approaches to battle diseases.
Zdravila in terapije bodo v prihodnosti bolj natančno izdelani za posameznega bolnika in bodo zato znatno izboljšali njihove življenjske pogoje.
Future medicines and therapies will be more precisely targeted to individual patients and thus improve their living conditions considerably.
Danes že vemo, da ne obstaja enotno zdravilo za določeno bolezen – ustrezna terapija je odvisna od številnih dejavnikov kot so spol, prenašanje zdravila ali posebne genetske značilnosti.
We know today that there is no single cure for a certain disease - the right therapy rather depends on a multitude of factors like gender, tolerability or specific genetic characteristics.
Evropa na tem področju nujno potrebuje večje naložbe v raziskave in razvoj, da bi bolnikom hitro zagotovili potencialne koristi.
Europe urgently needs more investment into research and development in this field in order to deliver potential benefits quickly to patients.
Zato je okrepljeno javno financiranje predkonkurenčnih raziskovalnih dejavnosti še posebej upravičeno in bo srednjeročno povzročilo večje naložbe iz privatnega sektorja ter tako naredilo Evropo privlačnejšo za nadarjene znanstvenike.
This is why enhanced public funding in pre-competitive research activities is particularly justified and will entail more private funding on the medium term and make Europe more attractive for talented scientist.
Treba je priznati, da je razvoj novih terapij zelo drag in nepredvidljiv podvig.
It has to be recognised that the development of a new therapy is a very costly and unpredictable undertaking.
Le majhen delež predlaganih zdravil pridobi dovoljenje za promet.
Only a small part of medicines candidates reaches the stage of a marketing authorisation.
Velika večina raziskovalnih dejavnosti je zaključena zaradi vprašanj varnosti ali učinkovitosti, potem ko so bile v razvojem procesu porabljene stotine milijonov evrov.
The vast majority of research activities ends due to safety or efficiency concerns after hundreds of millions of Euros have been spend during the development process.
Hkrati pa naložbe v biofarmacevtske raziskave v Evropi izgubljajo bitko z drugimi deli sveta, kot sta ZDA ali Japonska.
At the same time, the investment into biopharmaceutical research in Europe is loosing pace with other parts of the world like the US or Japan.
Zato pobuda za inovativna zdravila izhaja iz pravega izhodišča, ki predvideva uporabo javnih in privatnih sredstev za spodbujanje obsežnega vseevropskega raziskovanja, s pomočjo katerega bi čim prej ugotovili, če predlagano zdravilo lahko postane varno in učinkovito, ter spodbujanje sodelovanja med industrijo, znanostjo in neprofitnim sektorjem v korist celotne družbe.
Therefore, the IMI starts from the right point by using public and private money to boost large scale pan-European research in order to identify at the earliest possible stage whether a medicine candidate has the potential top become a safe and effective cure and to foster the collaboration between industry, academia and the non-profit sector for the benefit of the whole society.
Projekti v okviru pobude za inovativna zdravila bodo zagotovili, da bo obsežno raziskovanje, ki je potrebno za razvoj in potrjevanje novih orodij za odkrivanje in razvoj zdravil, dobro usklajeno in da se na ta način prepreči podvajanje dela.
IMI-projects will ensure that the substantial research needed to develop and validate new tools for drug discovery and development is well coordinated and will avoid the duplication of work.
Prek sodelovanja z velikimi podjetji bodo majhna raziskovalna središča dobila priložnost, da uresničijo svoje ideje.
Through the cooperation with big companies small scale research centres will also get the chance to get their ideas up and running.
Pripravljavka mnenja predlaga nekaj sprememb k predlogu Komisije, predvsem za zagotavljanje posodobljene raziskovalne agende in učinkovito posredovanje rezultatov javnosti in privatnemu sektorju.
The draftsman proposes a few amendments to the Commission's proposal, mainly aiming at ensuring an up-to date research agenda and an effective dissemination of the results to the public and private sector.
Poleg tega je treba zagotoviti večjo transparentnost s tesnejšim sodelovanjem Evropskega parlamenta, ki bi imenoval neodvisne predstavnike v upravni odbor podjetja za pobude za inovativna zdravila.
In addition, improved transparency through a closer involvement of the European Parliament should be ensured by appointing independent EP representatives to the IMI Board.
Medtem ko predlog daje pomembno vlogo enemu farmacevtskemu združenju, ki temelji na raziskavah, je treba opozoriti, da obstajajo tudi raziskovalne dejavnosti kjer se uporabljajo znane snovi, na primer na področju zeliščnih zdravil in zdravil brez recepta.
Whilst the proposal gives a prominent role to one research based pharmaceutical association, it should be noted that there are also research activities with known substances, e.g. in the area of herbal or non-prescription medicines.
Tem podjetjem in ustreznim trgovinskim združenjem je treba omogočiti sodelovanje v skupnem podjetju za pobudo za inovativna zdravila.
The participation of these companies and the relevant trade association in the IMI JU must be possible.
Na koncu je treba poudariti, da bodo poleg očitnih koristi za evropsko konkurenčnost in zmanjšanje tveganja s pomočjo kliničnega preskušanja zdravil na ljudeh projekti pobude za inovativna zdravila pozitivno vplivali na potrebo po poskusih na živalih.
Finally, it should be emphasised that beside evident benefits for Europe's competitiveness and diminished risk through human clinical trials, IMI projects will as well have a positive effect on the need for animal tests.
Nepotrebnim poskusom se bomo izognili, če bo možna neuspešnost predlaganega zdravila ugotovljena že v zgodnji fazi in če nova orodja v procesu razvijanja zdravil v večini primerov ne bodo odvisna od poskusov na živalih ampak od tehnik in vitro ali računalniških tehnologij.
Unnecessary tests will be avoided if a potential failure of a medicine candidate is recognised at an early stage and new tools in the drug development process will mostly not rely on animal tests but on new in-vitro techniques or computer based technologies.
(11) Skupna tehnološka pobuda za „inovativna zdravila“ bi morala predlagati usklajen pristop za odpravo ugotovljenih ozkih grl raziskav v postopku razvoja zdravil in podporo „predkonkurenčnih farmacevtskih raziskav in razvoja“, da se pospeši razvoj varnih in učinkovitejših zdravil za bolnike.
(11) The Joint Technology Initiative on "Innovative Medicines” should propose a coordinated approach to overcome identified research bottlenecks in the drug development process, and to support 'pre-competitive pharmaceutical research and development', in order to accelerate the development of safe and more effective medicines for patients.
V tem okviru je treba „predkonkurenčne farmacevtske raziskave in razvoj“ razumeti kot raziskave orodij in metodologij, ki se uporabljajo v postopku razvoja zdravil.
In the present context 'pre-competitive pharmaceutical research and development' should be understood as research on the tools and methodologies used in the drug development process.
Intelektualna lastnina, ki izhaja iz projekta pobude za inovativna zdravila, mora biti na voljo tretjim stranem pod poštenimi in razumnimi pogoji.
Intellectual property originating from an Innovative Medicines Initiative (IMI) project should be licensed to third parties on fair and reasonable terms.
Pojasniti je treba, da bo intelektualna lastnina, potrebna za uporabo orodij, ki so jih razvili partnerji projekta v okviru pobude za inovativna zdravila, na voljo tretjim stranem pod poštenimi in razumnimi pogoji.
It should be clarified that the intellectual property necessary to make use of the research tools developed by the partners of an IMI project, will be made available to third parties on fair and reasonable terms.
Priloga 7, točka (g)
Article 7, point (g)
(g) kvalificirane nepridobitne organizacije bolnikov glede na merila, ki jih določi Komisija .
(g) qualified non-profit patients organisations according to criteria to be established and defined by the Commission.
Obstaja jasna potreba, da Komisija določi merila za nepridobitne organizacije bolnikov v smislu preglednosti in sledljivosti kvalificiranja za to posebno financiranje.
There is a clear need for the Commission to establish certain criteria for non-profit patients organisations in terms of transparency and accountability to qualify for this particular funding.
Priloga, Člen 2, odstavek 2, točka (c)
Annex, Article 2, paragraph 2, point (c)
(c) zagotoviti vse potrebne prilagoditve raziskovalnega programa skupne tehnološke pobude za „inovativna zdravila“ v skladu z znanstvenim razvojem, doseženim med njegovim izvajanjem;
(c) to make any necessary adjustments to the Research Agenda of the Joint Technology Initiative on "Innovative Medicines" in light of scientific developments occurring during its implementation;
(c) redno pregledovati in zagotoviti vse potrebne prilagoditve raziskovalnega programa skupne tehnološke pobude za „inovativna zdravila“ v skladu z znanstvenim razvojem, doseženim med njegovim izvajanjem ter zagotoviti, da so prednostne naloge zdravstvenega varstva in potrebe pacientov v Evropi ustrezno obravnavane;
(c) to regularly review and make any necessary adjustments to the Research Agenda of the Joint Technology Initiative on "Innovative Medicines" in light of scientific developments occurring during its implementation and in order to ensure that the health care priorities and the needs of patients are adequately addressed in Europe ;
Raziskovalno agendo je treba sistematično pregledati, da bi zagotovili stalno upoštevanje znanstvenega napredka in koristi za paciente v Evropi.
The Research Agenda should be systematically reviewed in order to ensure that scientific progress and the benefit for patients in Europe are permanently taken into account.
Priloga, Člen 5, odstavek 1, točka (f a) (novo)
Annex, Article 5, paragraph 1, point (f a) (new)
(fa) Evropski parlament v upravni odbor imenuje dva neodvisna predstavnika in dva namestnika.
(fa) the European Parliament shall appoint two independent representatives and two substitutes to the Board.
Ker je Evropski parlament del proračunskega organa, bi moral biti zastopan v upravnem odboru.
Given the role of the European Parliament as part of the Budget Authority, it should be represented in the Board.
- po posvetovanju z znanstvenim odborom in skupino držav članic odobri predlog letnega proračuna, vključno z načrtom delovnih mest;
- prepare the annual budget proposal, including the staff establishment plan, after consultation with the Scientific Committee and the Member States Group ;
Izvršni direktor se mora posvetovati z drugimi ustreznimi telesi v okviru pobude za inovativna zdravila preden upravnemu odboru predloži predlog letnega proračuna.
The Executive Director should consult other relevant bodies of the IMI before submitting the annual budget proposal to the Board.
Priloga, Člen 6, odstavek 7, točka (i)
Annex, Article 6, paragraph 7, point (i)
(i) skliče letno srečanje foruma zainteresiranih strani, da zagotovi odprtost in preglednost dejavnosti skupnega podjetja za zainteresirane strani;
(i) call the annual meeting of the Stakeholder Forum, to ensure openness and transparency of the activities of the IMI Joint Undertaking with its stakeholders;
(i) skliče letno srečanje foruma zainteresiranih strani, odprto za ustrezne organizacije, ki se zanimajo za biomedicinske raziskave, da poročajo o dejavnostih v okviru pobude za inovativna zdravila ; s tem zagotovi odprtost in preglednost dejavnosti skupnega podjetja za zainteresirane strani;
(i) call the annual meeting of the Stakeholder Forum , an open meeting for relevant organisations with an interest in biomedical research to provide feedback on IMI activities , to ensure openness and transparency of the activities of the IMI Joint Undertaking with its stakeholders;
Pojasnitev narave letnega srečanja zainteresiranih strani, ki je namenjen zagotavljanju odprtosti in preglednosti dejavnosti skupnega podjetja za zainteresirane strani.
Clarification of the nature of the annual stakeholder meeting which aims at ensuring openness and transparency of the activities of the IMI Joint Undertaking with its stakeholders.
Izvršni direktor Evropskemu parlamentu predloži letno poročilo o dejavnostih.
The Executive Director shall present the annual activity report to the European Parliament.
V okviru rednega dialoga z Evropskim parlamentom izvršni direktor predstavi letno delovno poročilo.
As part of a regular dialogue with the European Parliament the Executive Director should present the Annual Activity Report to the European Parliament.
o predlogu Direktive Sveta o trženju razmnoževalnega materiala sadnih rastlin in sadnih rastlin, namenjenih za pridelavo sadja (preoblikovana različica)
on the proposal for a Council directive on the marketing of fruit plant propagating material and fruit plants intended for fruit production (Recast version)
(Preoblikovana različica - člen 80a poslovnika)
(Recast version - Rule 80a)
– ob upoštevanju člena 37 pogodbe o ES, v skladu s katerim se je Svet posvetoval s Parlamentom ( C6‑0093/2007 ),
– having regard to Article 37 of the EC Treaty, pursuant to which the Council consulted Parliament ( C6‑0093/2007 ),
– ob upoštevanju medinstitucionalnega sporazuma z dne 28. novembra 2007 o bolj sistematični uporabi prenovitve pravnih aktov
– having regard to the Interinstitutional Agreement of 28 November 2001 on a more structured use of the recasting technique for legal acts
OJ C 77 du 28.3.2002, p.
OJ C 77, 28.3.2002, p.
– ob upoštevanju člena 51 in člena 80 a poslovnika,
– having regard to Rule 51 and Rule 80a of its Rules of Procedure,
– ob upoštevanju poročila Odbora za kmetijstvo in razvoj podeželja ter pozitivnega mnenja Odbora za pravne zadeve ( A6–0480/2007 ),
– having regard to the report of the Committee on Agriculture and Rural Development and the opinion of the Committee on Legal Affairs ( A6‑0480/2007 ),
(6) Primerno je določiti predpise Skupnosti najprej za tiste rodove in vrste sadnih rastlin, ki so zelo pomembne za gospodarstvo Skupnosti, skupaj s postopkom Skupnosti za nadaljnje dodajanje rodov in vrst na seznam rodov in vrst, ki jih zadeva ta direktiva.
(6) It is appropriate to establish Community rules for those genera and species of fruit plant which are of major economic importance in the Community, with a Community procedure for adding further genera and species later to the list of genera and species to which this Directive applies.
Seznam bi moral vključevati tiste rodove in vrste, ki so v državah članicah najbolj razširjene in katerih razmnoževalni material predstavlja znaten trg , ki zajema več kot eno državo članico .
The genera and species listed should be those which are widely grown in Member States and for whose propagating material there is a substantial market which covers more than one Member State .
Seznam bi moral vključevati tiste rodove in vrste, ki so v državah članicah najbolj razširjene in katerih razmnoževalni material ima znaten trg.
The genera and species listed should be those which are widely grown in Member States and for whose propagating material there is a substantial.
Seznam direktive mora vsebovati vse rodove in vrste, ki so v poslovnem interesu.
The directive's list should contain all genera and species which are of commercial interest.
Sestava seznama z vključitvijo le tistih rodov in vrst, ki imajo znaten trg, ki zajema več kot eno državo članico, bi omejila učinkovitost direktive.
To draw up a list including only those genera and species for which there is a substantial market which covers more than one Member State would limit the effectiveness of the directive.
(11) Gensko spremenjene sadne rastline se ne smejo vpisati v katalog , če niso bili sprejeti vsi ustrezni ukrepi, da bi se izognili tveganju za zdravje ljudi ali okolje, kot je navedeno v Direktivi 2001/18/ES Evropskega parlamenta in Sveta z dne 12. marca 2001 o namernem sproščanju gensko spremenjenih organizmov v okolje in Uredbi (ES) Evropskega parlamenta in Sveta z dne 22. septembra 2003 o gensko spremenjenih živilih in krmi.
(11) Genetically modified fruit plants should not be accepted for registration in the catalogue unless all the appropriate measures have been taken to avoid any risk to human health or the environment as referred to in Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed.
(11) Gensko spremenjene sadne rastline se ne smejo vpisati v katalog , razen kot podlaga, na katero se cepijo želene sorte, in pod pogojem, da so bili sprejeti vsi ustrezni ukrepi, da bi se izognili tveganju za zdravje ljudi ali okolje, kot je navedeno v Direktivi 2001/18/ES Evropskega parlamenta in Sveta z dne 12. marca 2001 o namernem sproščanju gensko spremenjenih organizmov v okolje in Uredbi (ES) Evropskega parlamenta in Sveta z dne 22. septembra 2003 o gensko spremenjenih živilih in krmi.
(11) Genetically modified fruit plants should not be accepted for registration in the catalogue , except as stock onto which the desired varieties are to be grafted and providing all the appropriate measures have been taken to avoid any risk to human health or the environment as referred to in Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed.
V tem primeru je treba navesti namen genske spremembe.
In this case the purpose of genetic modification should be mentioned.
Znanstvenega razvoja, zlasti raziskav s ciljem iskanja podlage, ki je odporna na patogene organizme in zahteva le omejeno uporabo pesticidov, se ne sme prekiniti.
Scientific development, notably research aimed at finding stock which is resistant to pathogenic organisms and requires only the limited use of pesticides, must not stop.
Vendar se je treba strogo omejiti na material, namenjen za uporabo kot podlaga za cepitev sort in ne za uporabo pri pridelavi sadja, da bi se izognili nenadzorovani rasti gensko spremenjenih organizmov v okolju.
However, we must confine ourselves strictly to material intended for use as stock for grafting varieties and not for use in fruit production, so as to avoid the uncontrolled spread of genetically modified organisms in the environment.
Trgovino z gensko spremenjenim razmnoževalnim materialom za sadne rastline se dovoli le, če je namen genske spremembe dovolj utemeljen.
Trade in genetically modified propagating material for fruit plants should be permitted only where the purpose of genetic modification is sufficiently justified.
(14) Predvsem naloga dobaviteljev razmnoževalnega materiala in/ali sadnih rastlin je zagotoviti, da njihovi proizvodi izpolnjujejo pogoje, določene v tej direktivi.
(14) In the first instance it is the responsibility of the suppliers of propagating material and/or fruit plants to ensure that their products fulfil the conditions laid down in this Directive.
Primerno je opredeliti vlogo dobaviteljev in pogoje, ki veljajo zanje.
It is appropriate to define the role of the suppliers and the conditions to which they are to refer.
Dobavitelji morajo biti uradno registrirani, da se ustvari pregleden in gospodarsko veljaven postopek potrjevanja razmnoževalnega materiala in sadnih rastlin.
Suppliers should be officially registered in order to create a transparent and economically valid process of certification of propagating material and fruit plants.
Dobavitelji morajo biti uradno registrirani v registru , da se ustvari pregleden in gospodarsko veljaven postopek potrjevanja razmnoževalnega materiala in sadnih rastlin.
Suppliers should be officially registered in a register in order to create a transparent and economically valid process of certification of propagating material and fruit plants.
Registracija dobaviteljev v registru, ki bo na voljo zainteresiranim stranem, bo zagotovila verodostojnost in preglednost sistema.
The registration of suppliers in a register which will be available to stakeholders would ensure the reliability and transparency of the system.
(15) Dobavitelje, ki tržijo sadne rastline ali razmnoževalni material le osebam, ki se s pridelavo ali prodajo sadnih rastlin ali razmnoževalnega materiala ne ukvarjajo poklicno, bi bilo treba izvzeti iz obveznosti registracije.
(15) Suppliers who only market fruit plants or propagating material to persons not professionally engaged in the production or sale of fruit plants or propagating material should be exempted from the obligation of registration.
Stroški registracije dobaviteljem ne bi smeli predstavljati velikega bremena.
The cost of registering suppliers would not be substantial.
Če pa bi, bi bilo težje ugotoviti, ali razmnoževalni material, s katerim se trguje, na koncu prejmejo osebe, ki se s tem poklicno ukvarjajo.
However, if that were the case, it would be more difficult to establish whether the propagating material being traded ends in the hands of professionals or not.
Ta predlog spremembe hkrati zagotavlja preglednost sistema.
At the same time it ensures the transparency of the system.
(15a) Dobavitelji, ki tržijo razmnoževalni material ali sadne rastline, se morajo na tem področju specializirati.
(15a) Suppliers marketing propagating material or fruit plants should be specialised in this sector.
Dobavitelji, ki tržijo razmnoževalni material ali sadne rastline, morajo biti specializirani za ta sektor.
Suppliers possessing propagating material or fruit plants should be specialised in this sector.
(16a) Poleg tega mora razmnoževalni material, ki se uporabi, izvirati od uradno registriranih dobaviteljev, da lahko pridelovalec prejme sredstva Skupnosti za sajenje sadovnjakov.
(16a) Furthermore, and in order for a producer to receive Community funding for the planting of orchards, the propagating material to be used must originate from officially registered suppliers.